| abstract |
The present invention provides a composition comprising at least two targeting agents, wherein at least one first targeting agent recognizes keratin 7 peptide and / or fragment (s) thereof, and at least one second targeting agent is keratin 19 Peptide and / or fragment (s) thereof. The first and second targeting agents can specifically and simultaneously bind to the heterotypic complex of keratin 7 and keratin 19, and / or the fragment (s) thereof. The compositions of the present invention may be used to assess the outcome of treatment to diagnose and / or anticipate and / or predict the efficacy of treatment, or to evaluate the recurrence of malignant neoplastic disease, for example, lung cancer, bladder cancer, . |